Patents by Inventor Randy Ira Hecht

Randy Ira Hecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uses of FGF21 polypeptides comprising two or more mutations
    Patent number: 8361963
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: January 29, 2013
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120213779
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: May 3, 2012
    Publication date: August 23, 2012
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120177646
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 12, 2012
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120178685
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 12, 2012
    Applicant: Amgen Inc.
    Inventors: EDWARD JOHN BELOUSKI, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 mutants and uses thereof
    Patent number: 8188040
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: May 29, 2012
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120093815
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: December 16, 2011
    Publication date: April 19, 2012
    Applicant: Amgen Inc.
    Inventors: EDWARD JOHN BELOUSKI, MURIELLE MARIE ELLISON, AGNES EVA HAMBURGER, RANDY IRA HECHT, YUE-SHENG LI, MARK LEO MICHAELS, JEONGHOON SUN, JING XU
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120087920
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: December 15, 2011
    Publication date: April 12, 2012
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120052069
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: May 4, 2010
    Publication date: March 1, 2012
    Applicant: AMGEN INC
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20120003216
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: August 2, 2011
    Publication date: January 5, 2012
    Applicant: AMGEN INC.
    Inventors: EDWARD JOHN BELOUSKI, MURIELLE MARIE ELLISON, AGNES EVA HAMBURGER, RANDY IRA HECHT, YUE-SHENG LI, MARK LEO MICHAELS, JEONGHOON SUN, JING XU
  • OB fusion protein compositions and methods
    Patent number: 8080254
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: December 20, 2011
    Assignee: Amgen, Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pellymounter, Christopher Francis Toombs
  • FGF21 polypeptides comprising two or more mutations
    Patent number: 8034770
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: October 11, 2011
    Assignee: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 MUTANTS AND USES THEREOF
    Publication number: 20100285131
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: May 4, 2010
    Publication date: November 11, 2010
    Applicant: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • FGF21 Mutants and uses thereof
    Publication number: 20090305986
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 3, 2009
    Publication date: December 10, 2009
    Applicant: Amgen Inc.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • OB protein compositions and methods
    Patent number: 7524940
    Abstract: The present invention provides methods and compositions for treating excess weight by administering OB protein in a form for constant supply, at a dosage of less than or equal to about 1 mg protein/kg body weight/day. Compositions and methods used for production of recombinant murine and human OB protein are also provided. Compositions and methods for preparing recombinant murine methionyl OB protein and recombinant human methionyl OB protein, including DNA sequences, vectors, host cells, methods of fermentation, and methods of purification are provided herein.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: April 28, 2009
    Assignee: Amgen, Inc.
    Inventors: Mary Ann Pelleymounter, Randy Ira Hecht, Michael Benjamin Mann
  • OB PROTEIN COMPOSITIONS AND METHODS
    Publication number: 20090082275
    Abstract: The present invention provides methods and compositions for, for example, effecting weight loss and treating excess weight by administering OB protein, or a derivative thereof, in a form for constant supply, for example, continuous administration, at a dosage of less than or equal to about 1 mg protein/kg body weight/day. Compositions and methods used for production of recombinant murine and human OB protein are also provided. Compositions and methods for preparing recombinant murine methionyl OB protein and recombinant human methionyl OB protein, including DNA sequences, vectors, host cells, methods of fermentation, and methods of purification are provided herein.
    Type: Application
    Filed: November 12, 2008
    Publication date: March 26, 2009
    Applicant: AMGEN, INC.
    Inventors: Mary Ann Pelleymounter, Randy Ira Hecht, Michael Benjamin Mann
  • OB fusion protein compositions and methods
    Patent number: 7112659
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: September 26, 2006
    Assignee: Amgen, Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • OB fusion protein compositions and methods
    Patent number: 6936439
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: August 30, 2005
    Assignee: Amgen Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • OB fusion protein compositions and methods
    Publication number: 20040067520
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Application
    Filed: October 6, 2003
    Publication date: April 8, 2004
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • OB protein compositions and methods
    Publication number: 20030054997
    Abstract: The present invention provides methods and compositions for treating excess weight by administering OB protein in a form for constant supply, at a dosage of less than or equal to about 1 mg protein/kg body weight/day. Compositions and methods used for production of recombinant murine and human OB protein are also provided. Compositions and methods for preparing recombinant murine methionyl OB protein and recombinant human methionyl OB protein, including DNA sequences, vectors, host cells, methods of fermentation, and methods of purification are provided herein.
    Type: Application
    Filed: August 5, 2002
    Publication date: March 20, 2003
    Applicant: Amgen Inc.
    Inventors: Mary Ann Pelleymounter, Randy Ira Hecht, Michael Benjamin Mann
  • OB PROTEIN COMPOSITIONS AND METHODS
    Publication number: 20020009798
    Abstract: The present invention provides methods and compositions for treating excess weight by administering OB protein in a form for constant supply, at a dosage of less than or equal to about 1 mg protein/kg body weight/day. Compositions and methods used for production of recombinant murine and human OB protein are also provided. Compositions and methods for preparing recombinant murine methionyl OB protein and recombinant human methionyl OB protein, including DNA sequences, vectors, host cells, methods of fermentation, and methods of purification are provided herein.
    Type: Application
    Filed: August 2, 1999
    Publication date: January 24, 2002
    Inventors: MARY ANN PELLEYMOUNTER, RANDY IRA HECHT, MICHAEL BENJAMIN MANN